Active, not recruitingPHASE1, PHASE2NCT05293626
Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations
Studying Leber hereditary optic neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neurophth Therapeutics Inc
- Intervention
- NR082 Injection(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2029
Study locations (3)
- Stanford Byers Eye Institute, Palo Alto, California, United States
- University of Colorado Health Eye Center, Aurora, Colorado, United States
- Wills Eye Hospital, Neuro Ophthalmology Department, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05293626 on ClinicalTrials.govOther trials for Leber hereditary optic neuropathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT07406854A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 MutationWuhan Neurophth Biotechnology Limited Company
- RECRUITINGNANCT06682819Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)Hôpital Necker-Enfants Malades
- ENROLLING BY INVITATIONNCT06376279Genetic Diagnosis in Inborn Errors of MetabolismRegion Stockholm